Radioimmunotherapy in brain tumors

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Gliomas and meningiomas are the most frequent primary brain tumors. Surgery, external beam radiotherapy, and chemotherapy are, at present, the essential components in the therapeutic management of malignant brain masses. Nevertheless, these methods present limitations in terms of clinical response and rate of toxicity and morbidity. Because of the need for complementary or alternative treatment modalities, brain tumor cells have been persistently investigated to determine the presence of specific antigens, with the goal of produce\ing antibodies that might be useful as therapeutics. An emerging approach is targeted radiotherapy, a strategy that utilizes a molecular vehicle (antibody or peptide) to selectively deliver cytotoxic radiation emitted by a radionuclide to malignant cell populations. Although many types of labeled molecules have been investigated for targeted cancer radiotherapy, trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled monoclonal antibodies (MoAbs) as targeting vehicle. Recently, somatostatin receptors have been shown to be overexpressed in various brain tumors, especially meningiomas and glia-derived tumors. This evidence, following the clinical experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, has suggested that somatostatin analogs, coupled with appropriate radioisotopes, might also be of value in the treatment of brain tumors. The most commonly used radionuclides in targeted radiotherapy are beta-emitters, specifically: Yttrium-90 (90Y), Iodine-131 (131I), and Lutetium-177 (177Lu). The differences in physical half-life, the presence or absence of gamma rays, the energy, and consequently, the range of beta-particles in tissue are important variables with respect to the radiation dose that can be delivered to the tumor. Although targeted radiotherapy models have been principally evaluated for systemic administration, RIT and PRRT may also be applied loco-regionally, in order to reduce systemic toxicity. This chapter describes systemic and intracavitary use of RIT in high grade glioma. A brief report on PRRT in meningioma is also included.

Original languageEnglish
Title of host publicationNuclear Medicine Therapy: Principles and Clinical Applications
PublisherSpringer New York
Pages113-131
Number of pages19
ISBN (Print)9781461440215, 1461440203, 9781461440208
DOIs
Publication statusPublished - Aug 1 2013

Fingerprint

Radioimmunotherapy
Brain Neoplasms
Tumors
Brain
Radioisotopes
Radiotherapy
Peptide Receptors
Meningioma
Glioma
Therapeutics
Lutetium
Toxicity
Beta Particles
Radiation
Yttrium
Cells
Neoplasms
Somatostatin Receptors
Neuroendocrine Tumors
Antibodies

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Grana, C. M., & Paganelli, G. (2013). Radioimmunotherapy in brain tumors. In Nuclear Medicine Therapy: Principles and Clinical Applications (pp. 113-131). Springer New York. https://doi.org/10.1007/978-1-4614-4021-5_7

Radioimmunotherapy in brain tumors. / Grana, Chiara Maria; Paganelli, Giovanni.

Nuclear Medicine Therapy: Principles and Clinical Applications. Springer New York, 2013. p. 113-131.

Research output: Chapter in Book/Report/Conference proceedingChapter

Grana, CM & Paganelli, G 2013, Radioimmunotherapy in brain tumors. in Nuclear Medicine Therapy: Principles and Clinical Applications. Springer New York, pp. 113-131. https://doi.org/10.1007/978-1-4614-4021-5_7
Grana CM, Paganelli G. Radioimmunotherapy in brain tumors. In Nuclear Medicine Therapy: Principles and Clinical Applications. Springer New York. 2013. p. 113-131 https://doi.org/10.1007/978-1-4614-4021-5_7
Grana, Chiara Maria ; Paganelli, Giovanni. / Radioimmunotherapy in brain tumors. Nuclear Medicine Therapy: Principles and Clinical Applications. Springer New York, 2013. pp. 113-131
@inbook{86fcd188cde64fc68811baf204e72fba,
title = "Radioimmunotherapy in brain tumors",
abstract = "Gliomas and meningiomas are the most frequent primary brain tumors. Surgery, external beam radiotherapy, and chemotherapy are, at present, the essential components in the therapeutic management of malignant brain masses. Nevertheless, these methods present limitations in terms of clinical response and rate of toxicity and morbidity. Because of the need for complementary or alternative treatment modalities, brain tumor cells have been persistently investigated to determine the presence of specific antigens, with the goal of produce\ing antibodies that might be useful as therapeutics. An emerging approach is targeted radiotherapy, a strategy that utilizes a molecular vehicle (antibody or peptide) to selectively deliver cytotoxic radiation emitted by a radionuclide to malignant cell populations. Although many types of labeled molecules have been investigated for targeted cancer radiotherapy, trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled monoclonal antibodies (MoAbs) as targeting vehicle. Recently, somatostatin receptors have been shown to be overexpressed in various brain tumors, especially meningiomas and glia-derived tumors. This evidence, following the clinical experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, has suggested that somatostatin analogs, coupled with appropriate radioisotopes, might also be of value in the treatment of brain tumors. The most commonly used radionuclides in targeted radiotherapy are beta-emitters, specifically: Yttrium-90 (90Y), Iodine-131 (131I), and Lutetium-177 (177Lu). The differences in physical half-life, the presence or absence of gamma rays, the energy, and consequently, the range of beta-particles in tissue are important variables with respect to the radiation dose that can be delivered to the tumor. Although targeted radiotherapy models have been principally evaluated for systemic administration, RIT and PRRT may also be applied loco-regionally, in order to reduce systemic toxicity. This chapter describes systemic and intracavitary use of RIT in high grade glioma. A brief report on PRRT in meningioma is also included.",
author = "Grana, {Chiara Maria} and Giovanni Paganelli",
year = "2013",
month = "8",
day = "1",
doi = "10.1007/978-1-4614-4021-5_7",
language = "English",
isbn = "9781461440215",
pages = "113--131",
booktitle = "Nuclear Medicine Therapy: Principles and Clinical Applications",
publisher = "Springer New York",

}

TY - CHAP

T1 - Radioimmunotherapy in brain tumors

AU - Grana, Chiara Maria

AU - Paganelli, Giovanni

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Gliomas and meningiomas are the most frequent primary brain tumors. Surgery, external beam radiotherapy, and chemotherapy are, at present, the essential components in the therapeutic management of malignant brain masses. Nevertheless, these methods present limitations in terms of clinical response and rate of toxicity and morbidity. Because of the need for complementary or alternative treatment modalities, brain tumor cells have been persistently investigated to determine the presence of specific antigens, with the goal of produce\ing antibodies that might be useful as therapeutics. An emerging approach is targeted radiotherapy, a strategy that utilizes a molecular vehicle (antibody or peptide) to selectively deliver cytotoxic radiation emitted by a radionuclide to malignant cell populations. Although many types of labeled molecules have been investigated for targeted cancer radiotherapy, trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled monoclonal antibodies (MoAbs) as targeting vehicle. Recently, somatostatin receptors have been shown to be overexpressed in various brain tumors, especially meningiomas and glia-derived tumors. This evidence, following the clinical experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, has suggested that somatostatin analogs, coupled with appropriate radioisotopes, might also be of value in the treatment of brain tumors. The most commonly used radionuclides in targeted radiotherapy are beta-emitters, specifically: Yttrium-90 (90Y), Iodine-131 (131I), and Lutetium-177 (177Lu). The differences in physical half-life, the presence or absence of gamma rays, the energy, and consequently, the range of beta-particles in tissue are important variables with respect to the radiation dose that can be delivered to the tumor. Although targeted radiotherapy models have been principally evaluated for systemic administration, RIT and PRRT may also be applied loco-regionally, in order to reduce systemic toxicity. This chapter describes systemic and intracavitary use of RIT in high grade glioma. A brief report on PRRT in meningioma is also included.

AB - Gliomas and meningiomas are the most frequent primary brain tumors. Surgery, external beam radiotherapy, and chemotherapy are, at present, the essential components in the therapeutic management of malignant brain masses. Nevertheless, these methods present limitations in terms of clinical response and rate of toxicity and morbidity. Because of the need for complementary or alternative treatment modalities, brain tumor cells have been persistently investigated to determine the presence of specific antigens, with the goal of produce\ing antibodies that might be useful as therapeutics. An emerging approach is targeted radiotherapy, a strategy that utilizes a molecular vehicle (antibody or peptide) to selectively deliver cytotoxic radiation emitted by a radionuclide to malignant cell populations. Although many types of labeled molecules have been investigated for targeted cancer radiotherapy, trials in brain tumors have almost exclusively exploited the potential of radioimmunotherapy (RIT) by employing a radiolabeled monoclonal antibodies (MoAbs) as targeting vehicle. Recently, somatostatin receptors have been shown to be overexpressed in various brain tumors, especially meningiomas and glia-derived tumors. This evidence, following the clinical experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, has suggested that somatostatin analogs, coupled with appropriate radioisotopes, might also be of value in the treatment of brain tumors. The most commonly used radionuclides in targeted radiotherapy are beta-emitters, specifically: Yttrium-90 (90Y), Iodine-131 (131I), and Lutetium-177 (177Lu). The differences in physical half-life, the presence or absence of gamma rays, the energy, and consequently, the range of beta-particles in tissue are important variables with respect to the radiation dose that can be delivered to the tumor. Although targeted radiotherapy models have been principally evaluated for systemic administration, RIT and PRRT may also be applied loco-regionally, in order to reduce systemic toxicity. This chapter describes systemic and intracavitary use of RIT in high grade glioma. A brief report on PRRT in meningioma is also included.

UR - http://www.scopus.com/inward/record.url?scp=84929533391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929533391&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4021-5_7

DO - 10.1007/978-1-4614-4021-5_7

M3 - Chapter

SN - 9781461440215

SN - 1461440203

SN - 9781461440208

SP - 113

EP - 131

BT - Nuclear Medicine Therapy: Principles and Clinical Applications

PB - Springer New York

ER -